Parathyroid Disorders 1. 2.


Rubin MR, Silverberg SJ, Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle, J Clin Endocrinol Metab, 2005;90:5505–7.


Lundgren E, Lind L, Palmer M, et al., Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years, Surgery, 2001;130:978–85.


3. 4.


Adami S, Marcocci C, Gatti D, Epidemiology of primary hyperparathyroidism in Europe, J Bone Miner Res, 2002;17 (Suppl 2):N18–23.


Silverberg SJ, Lewiecki EM, Mosekilde L, et al., Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop, J Clin Endocrinol Metab, 2009;94:351–65.


5. Albright F, Reifenstein EC, The Parathyroid Glands and Metabolic Bone Disease, Williams and Wilkins Co, Baltimore, 1948.


6. Silverberg SJ, Bilezikian JP, The diagnosis and management of asymptomatic primary hyperparathyroidism, Nat Clin Pract Endocrinol Metab, 2006;2:494–503.


7.


Wermers RA, Khosla S, Atkinson EJ, et al., The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992, Ann Intern Med, 1997;126:433–40.


8.


Wermers RA, Khosla S, Atkinson EJ, et al., Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease, J Bone Miner Res, 2006;21:171–7.


9. 10. 11.


Bilezikian JP, Meng X, Shi Y, et al., Primary hyperparathyroidism in women: a tale of two cities-New York and Beijing, Int J Fertil Womens Med, 2000;45:158–65.


Lundgren E, Ljunghall S, Akerström G, et al., Case- control study on symptoms and signs of ‘asymptomatic’ primary hyperparathyroidism, Surgery, 1998;124:980–5.


Lundgren E, Szabo E, Ljunghall S, et al., Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism, BMJ, 1998;317:848–51.


12. 13.


Hagström E, Hellman P, Larsson TE, et al., Plasma parathyroid hormone and the risk of cardiovascular mortality in the community, Circulation, 2009;119:2765–71.


Fallo F, Camporese G, Capitelli E, et al., Ultrasound evaluation of carotid artery in primary


22.


hyperparathyroidism, J Clin Endocrinol Metab, 2003;88:2096–9.


14.


Piovesan A, Molineri N, Casasso F, et al., Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy, Clin Endocrinol (Oxf), 1999;50:321–8.


15. 16. 17.


Rubin MR, Maurer MS, McMahon DJ, et al., Arterial stiffness in mild primary hyperparathyroidism, J Clin Endocrinol Metab, 2005;90:3326–30.


Walker MD, Fleischer J, Rundek T, et al., Carotid vascular abnormalities in primary hyperparathyroidism, J Clin Endocrinol Metab, 2009;94:3849–56.


Rubin MR, Bilezikian JP, McMahon DJ, et al., The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years, J Clin Endocrinol Metab, 2008;93:3462–70.


18.


Bilezikian JP, Khan AA, Potts JT, Jr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop, J Clin Endocrinol Metab, 2009;94:335–9.


19. 20.


Bilezikian JP, Rubin M, Silverberg SJ, Asymptomatic primary hyperparathyroidism, Arq Bras Endocrinol Metabol, 2006;50:647–56.


Khan AA, Bilezikian JP, Potts JT Jr, The diagnosis and management of asymptomatic primary hyperparathyroidism revisited, J Clin Endocrinol Metab, 2009;94:333–4.


21.


Rao DS, Phillips ER, Divine GW, et al., Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism, J Clin Endocrinol Metab, 2004;89:5415–22.


Hedbäck G, Odén A, Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism, Eur J Endocrinol, 2003;148:413–21.


23.


Ambrogini E, Cetani F, Cianferotti L, et al., Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial, J Clin Endocrinol Metab, 2007;92:3114–21.


24.


Bollerslev J, Jansson S, Mollerup CL, et al., Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial, J Clin Endocrinol Metab,


28. 2007;92:1687–92. 25.


Walker MD, McMahon DJ, Inabnet WB, et al., Neuropsychological features in primary hyperparathyroidism: a prospective study, J Clin Endocrinol Metab, 2009;94:1951–8.


26. 27.


Hedback G, Tisell LE, Bengtsson BA, et al., Premature death in patients operated on for primary hyperparathyroidism, World J Surg, 1990;14:829–35.


Udelsman R, Pasieka JL, Sturgeon C, et al., Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop, J Clin Endocrino Metab, 2009;94:366–72.


Grey A, Lucas J, Horne A, et al., Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency, J Clin Endocrinol Metab, 2005;90:2122–6.


29.


Orr-Walker BJ, Evans MC, Clearwater JM, et al., Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women, Arch Intern Med, 2000;160:2161–6.


30.


Chesnut CH 3rd, McClung MR, Ensrud KE, et al., Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling, Am J Med, 1995;99:144–52.


31.


Khan AA, Bilezikian JP, Kung AW, et al., Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial, J Clin Endocrinol Metab, 2004;89:3319–25.


32. Amgen, Mimpara Summary of Product Characteristics (SmPC), EMEA, 2010.


33.


Marcocci C, Chanson P, Shoback D, et al., Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism, J Clin Endocrinol Metab, 2009;94:2766–72.


34.


Peacock M, Bilezikian JP, Klassen PS, et al., Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism, J Clin Endocrinol Metab, 2005;90:135–41.


35.


Peacock M, Bolognese MA, Borofsky M, et al., Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five- year study, 2009;94:4860–7.


58


EUROPEAN ENDOCRINOLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68